Hangzhou, China, Dec. 29, 2025 — WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a Chinese medical device supplier, today announced via its subsidiary Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and the latter’s Chinese subsidiaries that its affiliate Hunan Saitumofei Co., Ltd. has obtained manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II medical device, the Artificial Intelligence (“AI”)-Automated Human Blood Cell Morphology Analyzer. This regulatory clearance marks a milestone in WORK Medical’s R&D strategy and is expected to establish the Company’s new AI-powered device as a key driver of growth.
The analyzer is made up of a main unit and built-in analysis software. The main unit combines an optical imaging system, sample-handling module, barcode scanner, automatic oil-immersion unit, control board, and protective enclosure. It conducts differential white blood cell counts on human blood smears and measures morphological parameters of red blood cells and platelets, aiding clinicians in cell morphology screening. Leveraging advanced AI automation, the analyzer merges high-speed digital imaging, deep-learning algorithms, and a fully automated workflow to identify, pre-classify, and describe the morphology of white blood cells, red blood cells, and platelets in peripheral blood smears. Scheduled to enter production in the first half of 2026, the analyzer is designed to boost efficiency, consistency, and accuracy in microscopic examinations while lowering manual workload and operational expenses.
Mr. Shuang Wu, Chief Executive Officer and Chairman of the Board of Directors at WORK Medical, stated: “This new analyzer incorporates state-of-the-art AI technology into traditional medical testing, enhancing consistency, efficiency, and accuracy while reducing manual involvement and related costs. The device has evolved from an auxiliary image-reading tool to a fully automated, standardized, and remotely accessible core testing platform. With ongoing AI algorithm iterations and pipeline integration, it is anticipated to become standard equipment in hematology and oncology departments at tertiary hospitals and primary care laboratories, and aims to support early blood disorder screening, quality control improvements, and labor cost optimization. We are upbeat about the growth of this product line and its revenue potential for the Company.”
About WORK Medical Technology Group LTD
WORK Medical Technology Group LTD, via its subsidiary Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and the latter’s Chinese subsidiaries, is a Chinese medical device supplier that develops and manufactures Class I and II medical devices, and sells Class I and II disposable medical devices through its operating subsidiaries in China. The Company boasts a diverse product lineup of 21 items, including customized and multifunctional masks and other medical consumables. All products are available in 34 provincial-level administrative regions across China, with 15 of them sold in over 30 countries worldwide. The Company has received multiple quality-related manufacturing certifications and has registered 17 products with the U.S. Food and Drug Administration, enabling market access in the United States. For more details, please visit the Company’s website: .
Forward-Looking Statements
This press release contains forward-looking statements, including those made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements can be recognized by terms like “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations or similar expressions used to identify forward-looking statements. Any statements in this release that are not historical facts may be deemed forward-looking. All forward-looking statements in this press release are based solely on the Company’s current expectations, estimates, and projections as of the date of issuance and are subject to numerous risks and uncertainties that could cause actual results to differ significantly and adversely from those stated or implied by these forward-looking statements. While the Company believes the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee their accuracy. The Company cautions investors that actual results may vary materially from anticipated outcomes and encourages them to review other factors impacting future results outlined in the Company’s annual report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update forward-looking statements except as required by law.
For more information, please contact:
WORK Medical Technology Group LTD
Investor Relations Department
Email:
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email:
